Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
AbstractImmune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on available data, it’s obvious that ICB has limited success in PDACs, which can be explained by the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. In this review article, we focus on PD-L1 expression and microsatellite instability (MSI) in PDAC, and their roles as prognostic and predictive markers. We also discuss data supporting combination therapies to augment cancer immunity cycle. Combining anti-PD-1/PD-L1 agents with other modalities such as vaccines, chemotherapy, and radiation could potentially overcome resistance patterns and increase immune responsiveness in PDAC. View Full-Text
Share & Cite This Article
Macherla, S.; Laks, S.; Naqash, A.R.; Bulumulle, A.; Zervos, E.; Muzaffar, M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int. J. Mol. Sci. 2018, 19, 3505.
Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. International Journal of Molecular Sciences. 2018; 19(11):3505.Chicago/Turabian Style
Macherla, Shravanti; Laks, Shachar; Naqash, Abdul R.; Bulumulle, Anushi; Zervos, Emmanuel; Muzaffar, Mahvish. 2018. "Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer." Int. J. Mol. Sci. 19, no. 11: 3505.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.